Sign in
Severity of Diabetic Retinopathy as an Independent Risk Factor for Cerebral Vascular Accidents, Myocardial Infarctions, and All-Cause Mortality
Bobeck S Modjtahedi, MD
Annual Meeting Talks
2020
Risk of Sight-Threatening Diabetic Retinopathy with GLP-1 Receptor Agonists, SGLT2 Inhibitors, DPP-4 Inhibitors, and Sulfonylureas in Type 2 Diabetes
Andrew J. Barkmeier, MD
Updates from the Field
2024
Widefield Fluorescein Angiographic-Guided Aflibercept (WFFAGA) Monotherapy for Proliferative Diabetic Retinopathy (PDR)
Dennis M. Marcus, MD
2019
Category: Diabetic Retinopathy